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Abstract
Measures of immune outcomes in youth who initiate combination antiretroviral therapy (cART) 
early in HIV infection are limited.
Design—Adolescent Trials Network 061 examined changes over 48 weeks of cART in T cell 
subsets and markers of T cell and macrophage activation in subjects with pre-therapy CD4>350. 
All subjects had optimal viral suppression from weeks 24 through 48.
Methods—Subjects (n=48) initiated cART with tenofovir/emtricitabine plus ritonavir-boosted 
atazanavir. Data were collected at baseline and weeks 12, 24, and 48. Trends were compared to 
uninfected controls.
Results—Significant increases over 48 weeks were noted in all CD4 populations including total, 
naïve, central memory (CM), and effector memory RO (EM RO) and effector memory RA (EM 
RA) while numbers of CM and EMRO CD8 cells declined significantly. By week 48, CD4 naïve 
cells were similar to controls while CM CD4 cells remained significantly lower and EM RO and 
EM RA subsets were significantly higher. CD38 and HLA DR expression, both individually and 
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when co-expressed, decreased over 48 weeks of cART on CD8 cells but remained significantly 
higher than controls at week 48. In contrast, markers of macrophage activation measured by 
sCD14 and sCD163 in plasma did not change with cART and were significantly higher than 
controls.
Conclusion—In youth initiating early cART, CD4 cell reconstitution is robust with decreases in 
CD8 cells. However CD8 T cell and macrophage activation persists at higher levels than 
uninfected controls.
Introduction
Infection with HIV-1 continues to impact youth in the US.1,2 While treatment with 
antiretroviral therapy is now recommended for most infected individuals,3 data are limited 
on the outcomes of antiretroviral treatment in infected youth who are unique for several 
reasons. For example, compared to adults following continuous antiretroviral therapy 
(cART), immune reconstitution in younger individuals shows higher proportions of naïve T 
cells.4–8 The timing of sexual debut is often close to HIV-1 acquisition among behaviorally 
infected adolescents indicating a relatively short duration of infection prior to initiating 
therapy. In older adults longer duration of infection and lower nadir CD4+ T cell (CD4) 
counts can diminish the depth and breadth of immune reconstitution.9–12 Younger age 
predicts less inflammation-mediated morbidity and presents opportunities to reduce the 
inflammatory consequences of HIV-1 infection such as cardiovascular disease.
Even with optimal viral suppression and immune reconstitution, high levels of immune 
activation following cART persist. While lack of adherence is a major cause of loss of viral 
suppression among youth on cART,13–17 immune activation and chronic inflammation may 
also contribute to viral breakthrough.18 Initiation of therapy before immune decline could 
reduce immune activation to levels similar to a uninfected individuals. In this study we 
examined changes in the distribution of naïve, memory, and effector memory T cell 
populations and extent of T cell activation following 48 weeks of cART in a population of 
youth with pre-therapy CD4 counts above 350 cells/mm3. We also determined if early cART 
resulted in decline in macrophage activation biomarkers associated with inflammation 
including soluble CD14 (sCD14) and soluble CD163 (sCD163).
Materials & Methods
Population
One hundred subjects from 23 clinical sites were enrolled between 2007 and 2010 into the 
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) and the 
International Maternal, Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT) 
study ATN 061: Preservation and Expansion of T-cell Subsets Following HAART De-
intensification to Atazanavir/ritonavir. Of one hundred subjects enrolled, 75 were 
randomized to the early treatment arm with pre-entry CD4>350 cells/mm3 and begun on 
cART with tenofovir/emtricitabine plus ritonavir-boosted atazanavir after resistance testing. 
Forty-eight subjects achieved viral suppression, defined as HIV-1 RNA plasma viral load 
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(VL) below 100 copies by week 24 and maintained through week 48, and are included in 
these analyses.
Fifty-one HIV-1 uninfected participants (HIV-) based on single time-point laboratory 
studies, similar to study cohort for age, gender, and African American ethnicity, were 
enrolled from one site (University of South Florida) as controls. Inclusion criteria for control 
subjects included no chronic illnesses or conditions, no infections or recent immunizations 
prior to blood studies, and documented HIV-1 sero-negative status.
The study was approved by Institutional Review Boards at each participating site. A Data 
Safety and Monitoring Board appointed by the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development reviewed the data from the study semiannually.
Procedures
Analyses for T- cell subsets, plasma VL, extended flow cytometry, and plasma soluble 
factors were performed at entry and weeks 12, 24, and 48. Peripheral blood mononuclear 
cells (PBMC) were obtained by Ficoll-Hypaque density centrifugation and cryopreserved at 
−160°C.19 Plasma samples were stored at −80°C.
Flow cytometry analysis of T cells subsets
Cryopreserved PBMCs were thawed, re-suspended in phosphate buffered saline containing 
2% fetal bovine serum (PBS/2% FBS),20 divided into two tubes for incubation with anti-
CD197 (CCR7, BD Bioscience, San Jose, CA) at 37°C, 5 % CO2 for 30 minutes, followed 
by incubation at 4°C for 30 minutes in a mixture of anti-CD3, anti-CD45RA, anti-HLA-DR, 
anti-CD57 (all BD Bioscience, San Jose, CA), anti-CD38 (Life Technologies, Carlsbad, CA) 
and either anti-CD4 or anti-CD8 (BD Bioscience, San Jose, CA). Cells were washed and re-
suspended in PBS/2% FBS.
Markers of T cell differentiation/activation were analyzed with a multi-parameter LSR II 
flow cytometer (BD Bioscience, San Jose, CA). Lymphocytes were defined based on the 
forward scatter (FSC) and side scatter (SSC) from 100,000 events per sample. Lymphocyte 
subpopulations were subsequently acquired by gating on CD3+CD4+ or CD3+CD8+ cells 
identifying T helper and cytotoxic T cells, respectively. Naive CD4 and CD8 T cells were 
enumerated by gating CCR7+ and CD45RA+ cells, T central memory (TCM) by gating 
CD45RA− and CCR7+ T cells, T effector memory (EMRA) by gating CD45RA+ and 
CCR7−, and T effector RO cells (EMRO) by gating CD45RA− and CCR7− (Figure 1). Each 
subpopulation was individually analyzed for single expression and mean fluorescence 
intensity (MFI) of CD28, CD38, or HLA DR (Figure 1),21 as well as dual expression of 
CD38 and HLA DR. Data were acquired using BD FACSDiva acquisition software (BD 
Bioscience, San Jose CA) and analyzed with FlowJo v9.4.11 (Treestar, Inc, San Carlos, 
CA). Flow cytometry gates were established based on the cut-off determined by FMO 
controls.22
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Measurement of soluble markers of immune activation in plasma
Commercially available ELISA kits were used to detect sCD14 (R & D Systems, 
Minneapolis, MN), sCD27 (eBioscience, San Diego CA), and sCD163 (R & D Systems, 
Minneapolis, MN) within previously frozen plasma stored at −80°C. sCD14 was measured 
at a dilution factor 1:200 with a detection range of 250 – 8000 pg/ml; sCD27 at a dilution 
factor of 1:50, detection range 0.31 – 20 U/ml; and sCD163 at a dilution factor of 1:20, 
detection range of 1.6 – 100 ng/ml. The ELISA plates were read on Biotek® EL800 
automated microplate reader (Winooski, VT) and results were analyzed using KCjunior™ 
microplate data analysis software, version 1.41.5 (Biotek®, Winooski, VT).
Statistical methods
Expression of immunological markers and soluble factors was analyzed using slopes and 
two-sample comparisons with healthy controls. Slopes of expression intensities over 48 
weeks were estimated for each subject by linear regression and then analyzed by t-test to 
assess whether mean slope equaled zero. Baseline and week 48 values for subjects were 
compared with healthy controls using the Wilcoxon Rank-Sum test. Baseline and 48 week 
comparisons were conducted with the overall data, as well as data stratified by baseline CD4 
counts (≤500 cells/mm3 versus >500 cells/mm3). All p-values were two-sided with statistical 
significance set at <0.05. Analyses were performed using SAS version 9.2.23
Results
Study Population
Forty-eight of the 75 subjects (64%) randomized to the treatment arm fully suppressed VL 
to <100 copies/ml between 24 and 48 weeks with the combination of ritonavir-boosted 
atazanavir, tenofovir, and emcitribine. Only two subjects had viral loads over 100 after week 
24 (261 and 219 copies at week 36). Both subjects were below the level of detection with 
repeat testing and were continued on study. Baseline demographics of subjects who 
suppressed VL compared with the control group are shown in Table 1. The majority of 
subjects were male (87.5%), identified as African American (67%), and had CD4 counts 
above 500 cells/mm3 (58.33%). Substance use, including alcohol, tobacco, and marijuana, 
was similar between subjects and controls, as reported previously.24 Other psychosocial 
factors were not assessed as part of this study.
Expansion of CD4 and contraction of CD8 cells over 48 weeks on cART
When compared to control youth, HIV-1 infected youth had significantly lower baseline 
CD4 counts for total (p=0.0019), naïve (p=0.0055), and CM (p<0.0001) subsets (Figure 2A). 
EM RA were higher (p=0.0019), but EM RO cells were not significantly different 
(p=0.4573). Following cART, significant increases developed in all CD4 populations 
including total (<0.0001), naïve (p=0.0029), CM (p=0.0001), and EM RO (p<0.0001) and 
EM RA (p<0.0001) subsets (Figure 2A). When T cell subsets were compared after week 48 
of cART, mean total CD4 counts were higher and not different from control individuals 
(p=0.0543) (Figure 2A).
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Total CD8 T cells and CM, EM RA, and EM RO subsets were significantly higher between 
subjects and controls (p<0.0001 for each), with no differences in CD8 naïve cells 
(p=0.5275). (Figure 2B). Total CD8 T cells decreased after therapy initiation, although the 
overall trend was not significant (p=0.0674). While no significant trends appeared for CD8 
naïve or EM RA subpopulations, other populations, including CM (p<0.0001) and EM RO 
(p=0.0006) subsets, decreased (Figure 2B).
Changes among CD4 and CD8 T cell subsets were analyzed based on subjects grouped by 
baseline CD4 counts ≤500 or >500 cells/mm3. In each group, similar increases in total CD4 
T cells, as well as CM, EM RO and EM RA CD4 populations occurred. Subjects with entry 
CD4≤ 500 also showed significant increases in naïve cells (data not shown). For CD8 cells, 
subjects in each CD4 strata demonstrated significant decreases in CM and EM RO 
populations.
Week 48 lymphocyte subsets compared to controls
At week 48, mean total CD4 T cell counts were not significantly different from control 
individuals (p=0.0543) (Figure 2A). In subset analysis, cART resulted in normalizing of 
CD4 naïve cells to levels similar to controls (p=0.1946), CM cells remained lower 
(p<0.0001), while both EM RO and EM RA subsets were higher (p<0.0001 for both).
Total CD8 populations, as well as both EM RO and RA subsets were higher in subjects at 
week 48 than in controls (p<0.0001 for each), whereas naïve and CM subsets were similar. 
(Figure 2B) Although significant longitudinal decreases for some CD8 subsets (CM and EM 
RO) occurred in subjects, elevated CD8 T cells persisted at week 48 driven by higher EM 
RO and EM RA subsets.
Decreased but persistent CD8 activation despite virologic suppression
Immune activation within each CD8 T cell subset was assessed as percentage of cells 
expressing CD28, CD38 or HLA DR at week 48 relative to earlier time points (Figure 3). 
Control of VL resulted in significant longitudinal increases in the percentage of CD8 naïve, 
CM, EM RA, and EM RO subsets expressing CD28 (p<0.0001 for each). (Figure 3A) 
However, subjects at week 48 compared to controls had lower CD28 expression on naïve 
(p=0.0072), CM (p<0.0001), and EM RO (p<0.0001) CD8 subsets, consistent with 
persistent activation. Similar to down regulation of CD28, increased expression of CD38 
and HLA DR reflects T cell activation. The percentage of cells expressing CD38 was higher 
at baseline but declined on naïve, CM, EM RO, and EM RA CD8 subsets within subjects 
(p<0.0001 for each time point post therapy). Expression of CD38 remained significantly 
higher for all CD8 subsets (p<0.0001) and failed to normalize even after 48 weeks of cART 
when compared to controls. Similarly, the percentage of cells expressing HLA DR 
decreased at week 48 for all CD8 subsets within subjects (p<0.0001 for all). These decreases 
led to percentages for naïve and EM RA CD8 subsets that were similar to controls, while 
CM (p<0.0001) and EM RO (p<0.0001) subsets remained higher. Although co-expression of 
CD38 and HLA-DR declined for each CD8 subpopulation (p<0.0001 for all, data not 
shown), percentage co-expression remained elevated at week 48 for all subpopulations 
(p<0.0001 for naïve, CM, and EM RO; p=0.0002 for EM RA) compared to controls. 
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Assessment of activation markers on CD8 T cell subsets by MFI showed that by 48 weeks 
CD28 increased, while CD38 and HLA DR decreased significantly on naïve, CM, EMRA, 
and EMRO (p <0.001 for all) but failed to normalize compared to controls (p < 0.001) 
(Supplemental Table S1).
Soluble factors of inflammation and activation
The impact of cART on macrophage activation was evaluated by assessing changes over 48 
weeks of treatment in plasma levels of sCD14 and sCD163, markers of innate activation, 
along with sCD27, a soluble marker of lymphocyte activation. While sCD163 decreased, 
sCD14 and sCD27 remained similar to baseline levels (Figure 4), and each factor persisted 
at significantly higher levels compared to HIV-1 negative controls. The extent of elevation 
in sCD14, sCD163, and sCD27 did not correlate with the levels of CD8 T cell activation 
based on expression of HLADR or CD38 on naïve, CM, EMRA, or EMRO subsets either at 
entry or after 48 weeks (data not shown).
Discussion
Since the time that ATN 061 was initiated in 2008 , treatment guidelines have shifted to 
recommend cART at early stages of HIV infection as standard of care.3 As HIV incidence 
continues to be high in youth, especially ethnic minority young men who have sex with men 
(MSM), understanding the risks and benefits of early therapy in this population is 
essential.1,2 Treatment of young adults in early stage of disease, where there is a shorter 
interval from infection to treatment and higher capacity for immune reconstitution could 
result in preservation of T cell homeostasis,25,26 and lower the risk HIV inflammatory 
complications such as cardiovascular disease.4–12 In our study of youth who initiated 
treatment when CD4 counts were above 350 cells/mm3 or even greater than 500 cells/mm3, 
T cell reconstitution by 48 weeks was robust, T cell activation was diminished, while 
macrophage activation persisted. Thus, despite early treatment and successful viral control 
in this younger cohort, T cell activation and inflammation persisted similar to chronic 
infection in older adults.
The subjects in ATN 061 were therapy naïve, initiated treatment prior to immunologic 
deterioration, and were treated with the same antiretroviral regimen with close monitoring to 
assure documentation of viral suppression. At the time ATN 061 was implemented, 
atazanavir was a recommended first line component of cART. Subsequent availability of 
darunavir might have advantages for treatment of HIV-infected youth,27–29 although 
darunavir or atazanavir are similarly effective with similar metabolic profiles compared to 
efavirenz as part of cART,30,31 The HIV-uninfected controls and infected subjects in this 
study were similar for gender, age, and race, but co-existing conditions such as infection by 
herpes viruses, mycobacterium, or other sexually transmitted diseases that may be prevalent 
among the infected youth but were not captured as confounding variables, might contribute 
to immune activation. Although measures of immune activation and inflammation are not 
part of standard monitoring in the clinical setting, determination of levels in the research 
setting provides critical insights into the impact of therapy. In our study, viral suppression 
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was maintained even with persistent immune activation. Conversely, immune activation was 
independent of viral breakthrough.
While viral replication differentially impacts T cell immune activation, primarily within 
CD8 CM and EM populations,23,32–34 control of viral replication should reestablish 
distribution of populations that are poised to return to normal levels.35 The capacity to 
rapidly express or down-regulate activation markers on CM and EM CD8 cell subsets 
suggests that assessment of discrete T cell populations has utility in monitoring immune 
activation in HIV-infected patients on cART as the extent of CD38 expression within CD8 
subsets and levels of cell-associated virus predict disease progression in untreated HIV-
infected adults.36 A surprising result among the youth with sustained viral suppression after 
48 weeks of cART was continued elevation in CD38 on CM and EM CD8 T cells and the 
failure to normalize CD28 when compared to uninfected controls. Longer duration of 
optimal viral suppression may be needed before these signs of T cell activation decline in 
younger individuals.
In HIV-infected older adults who initiate therapy after CD4 counts decline to less than 350 
cells/mm3, the extent to which CD4 cells normalize is much lower than in adolescents who 
initiate ART early in infection.4,5,37,38 Early therapy and persistence of thymic function is 
associated with improved immunologic outcomes in adults, children and adolescents treated 
with antiretroviral therapy.4–12,25,26 While gains in naïve CD4 cell T cells occur in most 
youth in our study, increases are most apparent among subjects with lower baseline CD4 
counts at baseline; by 48 weeks of cART naïve CD4 T cells were similar to uninfected youth 
reflective of restored T cell homeostasis.
HIV-1 infection primes macrophages for activation and accentuates LPS-induced 
macrophage activation through TLR-4, as measured by the levels of sCD14 and sCD163 in 
the plasma.39–43 There was no correlation between changes in macrophage activation and 
the extent of T cell activation when expression of CD38 and HLADR expression was 
correlated to levels of sCD14 and sCD163. These results further illustrate independent 
mechanisms of innate and adaptive immune activation. Elevations in sCD14 and sCD163 
persisted in spite of cART and were significantly higher than controls. Macrophage 
activation contributes to the long-term inflammatory complications of HIV-infection and 
appears to be independent of viral replication.44–46 Persistent macrophage mediated 
inflammation among youth who are asymptomatic with normal CD4 cell counts emphasizes 
the need for early interventions to reduce the long term inflammatory consequences of HIV 
infection.
sCD27 is a member of the tumor necrosis family released into the plasma following 
lymphocyte activation47 and like activation markers measure using flow cytometry, 
persistence of sCD27 in the plasma indicates ongoing immune activation.47–49 Elevated 
level of sCD27 when compared to controls further supports the observation that lymphocyte 
activation is not completely reversed by effective cART and provides another biomarker of 
lymphocyte activation that is not dependent on extended flow cytometry. Previous studies in 
adults and children show continued gains in CD4 cells and declines in inflammatory markers 
can be achieved with long term viral suppression but years of treatment are required.50–52
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Immune activation during early infection is independently associated with CD4 cell loss in 
untreated individuals.53 Data in older adults indicate that the impact of CD8 cell activation 
on AIDS or non-AIDS events is confounded by age with those subjects over 50 more at risk 
for co-morbid events.54 CD38 expression on CD8 cells is associated with disease 
progression in adolescents as measured by CDC disease classification.34 The long term 
follow-up of the subjects enrolled in ATN 061 will prove whether expression of CD38 on 
CM and EM CD8 cells can predict viral failure while receiving cART and better understand 
the impact of initial immune activation and inflammation on treatment outcomes in young 
adults.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
This work was supported by The Adolescent Trials Network for HIV/AIDS Interventions (ATN) from the National 
Institutes of Health [U01 HD 040533 and U01 HD 040474] through the Eunice Kennedy Shriver National Institute 
of Child Health and Human Development (B. Kapogiannis), with supplemental funding from the National Institutes 
on Drug Abuse (K. Davenny) and Mental Health (P. Brouwers, S. Allison). It was also supported by R01 DA 
DA031017 (M. Goodenow and J. Sleasman). The protocol was co-endorsed by the International Maternal Pediatric 
Adolescent AIDS Clinical Trials Group. Support for the International Maternal Pediatric Adolescent AIDS Clinical 
Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National 
Institute of Mental Health (NIMH) [U01 A1068632]. The study was scientifically reviewed by the ATN’s 
Therapeutic Leadership Group. Network, scientific and logistical support was provided by the ATN Coordinating 
Center (C. Wilson, C. Partlow) at The University of Alabama at Birmingham. Network operations and analytic 
support was provided by the ATN Data and Operations Center at Westat, Inc. (J. Korelitz, B. Driver, G. Price).
The following ATN sites participated in this study: University of South Florida, Tampa (Emmanuel, Lujan-
Zilberman, Julian), Children’s Hospital of Los Angeles (Belzer, Flores, Tucker), University of Southern California 
at Los Angeles (Kovacs, Homans, Lozano), Children’s National Medical Center (D’Angelo, Hagler, Trexler), 
Children’s Hospital of Philadelphia (Douglas, Tanney, DiBenedetto), John H. Stroger Jr. Hospital of Cook County, 
and the Ruth M. Rothstein CORE Center (Martinez, Bojan, Jackson), University of Puerto Rico (Febo, Ayala-
Flores, Fuentes-Gomez), Montefiore Medical Center (Futterman, Enriquez-Bruce, Campos), Mount Sinai Medical 
Center (Steever, Geiger), University of California-San Francisco (Moscicki, Auerswald, Irish), Tulane University 
Health Sciences Center (Abdalian, Kozina, Baker), University of Maryland (Peralta, Gorle), University of Miami 
School of Medicine (Friedman, Maturo, Major-Wilson), Children’s Diagnostic and Treatment Center (Puga, 
Leonard, Inman), St. Jude’s Children’s Research Hospital (Flynn, Dillard), and Children’s Memorial (Garofalo, 
Brennan, Flanagan).
The following IMPAACT sites participated in the study: Children’s Hospital of Michigan – Wayne State (Moore, 
Rongkavilit, Hancock), Duke University Medical Center Pediatric CRS (Cunningham, Wilson), Johns Hopkins 
University (Ellen, Chang, Noletto), New Jersey Medical School CTU/CRS (Dieudonne, Bettica, Monti), St. Jude/
Memphis CTU/CRS (Flynn, Dillard, McKinley), University of Colorado School of Medicine/The Children’s 
Hospital (Reirden, Kahn, Witte) University of Southern California Medical Center (Homans, Lozano), Howard 
University Hospital (Rana, Deressa),
Four of the ATN and IMPAACT sites utilized their General Clinical Research Center (GCRC)/Pediatric Clinical 
Research Center (PCRC) for the study. The centers were supported by grants from the General Clinical Research 
Center Program of the National Center for Research Resources (NCRR), National Institutes of Health, Department 
of Health and Human Services as follows: Children's National Medical Center, M01RR020359; Howard University 
Hospital, MO1-RR010284; University of California at San Francisco, UL1 RR024131; and University of Colorado 
School of Medicine/Children’s Hospital, UL1 RR025780. The University of Pennsylvania/Children's Hospital of 
Philadelphia utilized its Institutional Clinical and Translational Science Award Research Center (CTRC), supported 
by grant UL1 RR024134 from NCRR. The Tulane University Health Sciences Center utilized its Clinical and 
Translational Research Center (CTRC) for the study which was supported in whole or in part by funds provided 
through the Louisiana Board of Regents RC/EEP (RC/EEP - 06).
Atazanavir was provided by Bristol Myers Scribb with support from Jonathon Uy.
Rudy et al. Page 8
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
We thank the ATN Community Advisory Board and the youth who participated in the study. We also thank Susan 
Lukas for assistance with flow cytometry and ELISA testing and Theresa Considine for assistance with manuscript 
preparation.
References
1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008; 
300:520–529. [PubMed: 18677024] 
2. Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas. Centers for 
Disease Control and Prevention; 2010. at http://www.cdc.gov/hiv/library/reports/surveillance/2010/
surveillance_Report_vol_22.html. [Accessed June 13, 2013]
3. [Accessed June 13, 2013] Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults 
and Adolescents. at http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-
guidelines/0.
4. Li T, Wu N, Dai Y, et al. Reduced thymic output is a major mechanism of immune reconstitution 
failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis. 2011; 
53:944–951. [PubMed: 21960716] 
5. Kolte L, Dreves AM, Ersboll AK, et al. Association between larger thymic size and higher thymic 
output in human immunodeficiency virus-infected patients receiving highly active antiretroviral 
therapy. J Infect Dis. 2002; 185:1578–1585. [PubMed: 12023763] 
6. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the 
treatment of HIV infection. Nature. 1998; 396:690–695. [PubMed: 9872319] 
7. Resino S, Seoane E, Perez A, Ruiz-Mateos E, Leal M, Munoz-Fernandez MA. Different profiles of 
immune reconstitution in children and adults with HIV-infection after highly active antiretroviral 
therapy. BMC Infect Dis. 2006; 6:112. [PubMed: 16839416] 
8. Franco JM, Leon-Leal JA, Leal M, et al. CD4+ and CD8+ T lymphocyte regeneration after anti-
retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol. 2000; 119:493–
498. [PubMed: 10691922] 
9. Engsig FN, Gerstoft J, Kronborg G, et al. Long-term mortality in HIV patients virally suppressed for 
more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis. 2010; 
10:1471–2334.
10. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral 
therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007; 44:441–446. 
[PubMed: 17205456] 
11. D'Amico R, Yang Y, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited 
immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of 
immunophenotypic marker results of AACTG 5067. J Clin Immunol. 2005; 25:106–115. 
[PubMed: 15821887] 
12. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance 
of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent 
antiretroviral therapy. Clin Infect Dis. 2005; 41:361–372. [PubMed: 16007534] 
13. Ryscavage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and 
young adults in adult HIV care. J Acquir Immune Defic Syndr. 2011; 58:193–197. [PubMed: 
21826014] 
14. Bygrave H, Mtangirwa J, Ncube K, Ford N, Kranzer K, Munyaradzi D. Antiretroviral therapy 
outcomes among adolescents and youth in rural Zimbabwe. PLoS One. 2012; 7:20.
15. Evans D, Menezes C, Mahomed K, et al. Treatment Outcomes of HIV-Infected Adolescents 
Attending Public-Sector HIV Clinics Across Gauteng and Mpumalanga, South Africa. AIDS Res 
Hum Retroviruses. 2013; 29:892–900. [PubMed: 23373540] 
16. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Patient-related risks for nonadherence to 
antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and 
interactions. AIDS Patient Care STDS. 2009; 23:185–194. [PubMed: 19866536] 
17. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Prevalence and interactions of patient-related 
risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United 
States. AIDS Patient Care STDS. 2010; 24:97–104. [PubMed: 20059354] 
Rudy et al. Page 9
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
18. Syed SS, Balluz RS, Kabagambe EK, et al. Assessment of biomarkers of cardiovascular risk 
among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an 
early indicator of endothelial inflammation. AIDS Res Hum Retroviruses. 2013; 29:493–500. 
[PubMed: 23062187] 
19. Kleeberger CA, Lyles RH, Margolick JB, Rinaldo CR, Phair JP, Giorgi JV. Viability and recovery 
of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin 
Diagn Lab Immunol. 1999; 6:14–19. [PubMed: 9874657] 
20. Sleasman JW, Leon BH, Aleixo LF, Rojas M, Goodenow MM. Immunomagnetic selection of 
purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following 
cryopreservation. Clin Diagn Lab Immunol. 1997; 4:653–658. [PubMed: 9384284] 
21. Oswald-Richter K, Grill SM, Leelawong M, et al. Identification of a CCR5-expressing T cell 
subset that is resistant to R5-tropic HIV infection. PLoS Pathog. 2007; 3:e58. [PubMed: 
17465678] 
22. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the 
immune system. Nat Rev Immunol. 2004; 4:648–655. [PubMed: 15286731] 
23. [Accessed May 15, 2014] SAS OnlineDoc 9.1.3. at http://support.sas.com/onlinedoc/913/
docMainpage.jsp )
24. Nichols SL, Lowe A, Zhang X, et al. Concordance between self-reported substance use and 
toxicology among HIV-infected and uninfected at risk youth. Drug and alcohol dependence. 2014; 
134:376–382. [PubMed: 24309297] 
25. Rudy BJ, Lindsey JC, Flynn PM, et al. Immune reconstitution and predictors of virologic failure in 
adolescents infected through risk behaviors and initiating HAART: week 60 results from the 
PACTG 381 cohort. AIDS research and human retroviruses. 2006; 22:213–221. [PubMed: 
16545007] 
26. Rudy BJ, Crowley-Nowick PA, Douglas SD. Immunology and the REACH study: HIV 
immunology and preliminary findings. Reaching for Excellence in Adolescent Care and Health. 
The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 
2001; 29:39–48. [PubMed: 11530302] 
27. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance 
monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority 
trial, MONOI-ANRS 136. Aids. 2010; 24:2365–2374. [PubMed: 20802297] 
28. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without 
nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010; 24:223–230. 
[PubMed: 20010070] 
29. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: 
week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus 
two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA 
copies/mL at baseline. HIV Med. 2012; 13:398–405. [PubMed: 22413874] 
30. Imaz A, Llibre JM, Navarro J, et al. Effectiveness of efavirenz compared with ritonavir-boosted 
protease inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 
100,000 copies/ml. Antiviral therapy. 2014
31. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/
ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum 
Retroviruses. 2012; 28:1184–1195. [PubMed: 22352336] 
32. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains 
in human immunodeficiency virus-infected patients with sustained viral suppression during 
antiretroviral therapy. J Infect Dis. 2003; 187:1534–1543. [PubMed: 12721933] 
33. Mildvan D, Bosch RJ, Kim RS, et al. Immunophenotypic markers and antiretroviral therapy 
(IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004; 
189:1811–1820. [PubMed: 15122517] 
34. Wilson CM, Ellenberg JH, Douglas SD, Moscicki AB, Holland CA. CD8+CD38+ T cells but not 
HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ 
adolescent population. AIDS Res Hum Retroviruses. 2004; 20:263–269. [PubMed: 15117448] 
Rudy et al. Page 10
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
35. Masopust D, Picker LJ. Hidden memories: frontline memory T cells and early pathogen 
interception. J Immunol. 2012; 188:5811–5817. [PubMed: 22675215] 
36. Mahnke YD, Song K, Sauer MM, et al. Early immunologic and virologic predictors of clinical 
HIV-1 disease progression. Aids. 2013; 27:697–706. [PubMed: 23211771] 
37. Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive 
T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012; 8:5.
38. Zeng M, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: life or death for 
T cells. Trends Immunol. 2012; 33:306–314. [PubMed: 22613276] 
39. Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM. HIV-1 activates macrophages 
independent of Toll-like receptors. PLoS One. 2008; 3:2.
40. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV 
disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004; 200:749–759. 
[PubMed: 15365096] 
41. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nat Med. 2006; 12:1365–1371. [PubMed: 17115046] 
42. Hayes TL, Asmuth DM, Critchfield JW, et al. Impact of highly active antiretroviral therapy 
initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa. Aids. 2013; 27:867–877. 
[PubMed: 23262500] 
43. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a 
novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral 
therapy. J Infect Dis. 2011; 204:154–163. [PubMed: 21628670] 
44. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in 
HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010; 
202:723–733. [PubMed: 20629534] 
45. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune 
activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV 
infection. J Infect Dis. 2009; 199:1177–1185. [PubMed: 19265479] 
46. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained 
failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active 
antiretroviral therapy. Aids. 2008; 22:2035–2038. [PubMed: 18784466] 
47. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through 
CD27-CD70 interactions. Semin Immunol. 1998; 10:491–499. [PubMed: 9826582] 
48. Yin L, Rodriguez CA, Hou W, et al. Antiretroviral therapy corrects HIV-1-induced expansion of 
CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells. J Allergy Clin Immunol. 2008; 
122:166–172. [PubMed: 18538835] 
49. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophage 
activation unrelated to HIV-1 levels or T-cell activation following therapy. Aids. 2010; 24:1281–
1290. [PubMed: 20559035] 
50. Ronsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR. T-cell subset distribution in 
HIV-1-infected patients after 12 years of treatment-induced viremic suppression. J Acquir Immune 
Defic Syndr. 2012; 61:270–278. [PubMed: 22614900] 
51. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent 
viral control with antiretroviral therapy. Aids. 2010; 24:614–617. [PubMed: 19952710] 
52. Hughes RA, Sterne JA, Walsh J, et al. Long-term trends in CD4 cell counts and impact of viral 
failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. 
HIV Med. 2011; 12:583–593. [PubMed: 21569188] 
53. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection 
predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004; 104:942–947. 
[PubMed: 15117761] 
54. Lok JJ, Hunt PW, Collier AC, et al. The impact of age on the prognostic capacity of CD8+ T-cell 
activation during suppressive antiretroviral therapy. Aids. 2013; 27:2101–2110. [PubMed: 
24326304] 
Rudy et al. Page 11
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Rudy et al. Page 12
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. T cell subsets and expression of activation markers in PBMC
Flow cytometry of T cells gated on CD3+CD4+ T cells (panels A and B) or CD3+CD8+ T 
cells (panels C and D) from representative uninfected (HIV−) and HIV-infected (HIV+) 
subjects. Panels A and C show density contour plots of CCR7 and CD45RA expression in 
CD4+ T cells (A & B) and CD8+ T cells (C & D). T cell subsets are defined as Naïve (CD3+ 
CD4/8+ CD45RA+ CCR7+); TCM (CD3+ CD4/8+ CD45RA− CCR7+); TEMRO (CD3+ 
CD4/8+ CD45RA−CCR7−); and TEMRA (CD3+ CD4/8+ CD45RA+ CCR7−). Percentage of 
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cells based on FMO controls are shown for each quadrant. Activation markers CD28, CD38, 
and HLA DR are shown (B & D) as overlaid histogram plots for each subset.
Rudy et al. Page 14
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Trends in mean CD8+ and CD4+ T cells following antiretroviral therapy
The y axis shows change in total cells/mm3 for CD4+ T-cell subsets (panel A), change in 
CD4+ T-cell in HIV+ subjects with baseline CD4+ T-cells >500 cells/mm3 (panel B), and 
with baseline CD4+ T-cells ≤ 500 cells/mm3 (panel C). Change in CD8+ T-cell subsets 
(panel D), CD8+ T-cell subsets in HIV+ subjects with baseline CD4+ T-cells > 500 
cells/mm3 (panel E), and with baseline CD4+ T-cells ≤ 500 cells/mm3 (panel F) are also 
shown. Bars represent baseline ( ), week 12 ( ), week 24 ( ), week 48 ( ), and HIV − 
controls ( ) and are shown for each subset. Significant changes over 48 weeks are shown 
with arrows. Changes from entry to 48 weeks among HIV+ subjects are represented with (*) 
(p<0.05, Wilcoxon Rank-Sum test). Significant differences between HIV+ subjects at 
baseline to HIV− controls and HIV+ subjects at 48 weeks to HIV− controls are shown with 
(†) and (‡), respectively (p<0.05, Wilcoxon Rank-Sum test). Error bar indicates 1 standard 
deviation.
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Figure 3. Trends in mean expression of T cell activation markers on CD8+ T cells
Change in percent expression of CD28 (panel A), CD38 (panel B), and HLA-DR (panel C) 
are shown for each subpopulation. Bars represent baseline ( ), week 12 ( ), week 24 ( ), 
week 48 ( ), and HIV− controls ( ). Significant changes over 48 weeks are shown with 
arrows. Changes from entry to 48 weeks among HIV+ subjects are represented with (*) 
(p<0.05, Wilcoxon Rank-Sum test). Significant differences between HIV+ subjects at 
baseline to HIV− controls and HIV+ subjects at 48 weeks to HIV− controls are shown with 
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(†) and (‡), respectively (p<0.05, Wilcoxon Rank-Sum test). Error bar indicates 1 standard 
deviation.
Rudy et al. Page 17
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. Trends in mean levels of plasma biomarkers of macrophage and lymphocyte activation
Panels show levels of sCD14 levels (ng/ml) (panel A), sCD27 levels (U/ml) (panel B) and 
sCD163 levels (ng/ml) (panel C). The horizontal red line indicates mean values. Significant 
changes between baseline and 48 weeks in HIV+ subjects are represented with * (p<0.05, 
Wilcoxon Rank-Sum test). Significant differences between HIV+ subjects and HIV− 
controls are shown with † (p<0.05, Wilcoxon Rank-Sum test).
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Table 1
Baseline and Demographic Data
Variable
HIV infected
(N=48)
HIV
uninfected
(N=52) p-value
Age at Entry (Years) - Continuous
  Mean (SD) 20.90 (1.55) 21.62 (2.11) 0.0533
  Range 18 – 24 18 – 25
Age at Entry (Years) - Categorical 0.2160
  18 – 20 21 (43.75) 16 (30.77)
  Over 21 27 (56.75) 36 (69.23)
Gender 0.1317
  Male 42 (87.50) 39 (75.00)
  Female 6 (12.50) 13 (25.00)
Race 1.0000
  African American 32 (66.67) 35 (67.31)
  Other 16 (33.33) 17 (32.69)
Baseline CD4+ Count 0.0028
  < 350 0 (0) 4 (7.69)
  350 – 500 20 (41.67) 8 (15.38)
  > 500 28 (58.33) 40 (76.92)
Baseline CD4+ Percent <0.0001
  < 15% 2 (4.17) 1 (1.92)
  15-25% 19 (39.58)) 1 (1.92)
  > 25% 27 (56.25) 50 (96.15)
Baseline CD4+ Count
  Mean (SD) 553 (158) 730 (284) 0.0002
  Range 355 – 1107 192 – 1416
Baseline CD4+ Percent (%)
  Mean (SD) 27.07 (8.60) 41.94 (9.70) <0.0001
  Range 0.19 – 55.00 12.00 – 60.00
Baseline viral load
  Mean (SD) 20916 (21574) NA
  Range 1152 – 88900
CD4 count, CD4 percentage and Viral Load from the Pre-Entry visits were used as Baseline. P-values were calculated using Fishers exact test for 
categorical variables and t-test for continuous variables.
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